ZYPREXA ZYDIS Drug Patent Profile

Which patents cover Zyprexa Zydis, and what generic alternatives are available?

Zyprexa Zydis is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in ZYPREXA ZYDIS is olanzapine. There are thirty-three drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the olanzapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyprexa Zydis

A generic version of ZYPREXA ZYDIS was approved as olanzapine by SANDOZ INC on October 24^th, 2011.

Summary for ZYPREXA ZYDIS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	147
Clinical Trials:	132
Drug Prices:	Drug price information for ZYPREXA ZYDIS
DailyMed Link:	ZYPREXA ZYDIS at DailyMed

See drug prices for ZYPREXA ZYDIS

Recent Clinical Trials for ZYPREXA ZYDIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Branded Pharmaceutical Products R&D, Inc.	PHASE1
Teva Branded Pharmaceutical Products R&D LLC	PHASE1
OHSU Knight Cancer Institute	Phase 2

See all ZYPREXA ZYDIS clinical trials

Pharmacology for ZYPREXA ZYDIS

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ZYPREXA ZYDIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-001	Apr 6, 2000	AB	RX	Yes	Yes
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-004	Apr 6, 2000	AB	RX	Yes	No
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000	AB	RX	Yes	No
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-003	Apr 6, 2000	AB	RX	Yes	No

Expired US Patents for ZYPREXA ZYDIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-003	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-001	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-001	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-003	Apr 6, 2000

EU/EMA Drug Approvals for ZYPREXA ZYDIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Zyprexa Velotab	olanzapine	EMEA/H/C/000287AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	no	no	no	2000-02-03
Eli Lilly Nederland B.V.	Zypadhera	olanzapine	EMEA/H/C/000890Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.	Authorised	no	no	no	2008-11-19
Eli Lilly Nederland B.V.	Zyprexa	olanzapine	EMEA/H/C/000115Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.	Authorised	no	no	no	1996-09-27
Krka	Zalasta	olanzapine	EMEA/H/C/000792Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-09-27
Mylan Pharmaceuticals Limited	Olanzapine Mylan	olanzapine	EMEA/H/C/000961AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2008-10-06
Teva B.V.	Olanzapine Teva	olanzapine	EMEA/H/C/000810AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-12-12
Apotex Europe BV	Olanzapine Apotex	olanzapine	EMEA/H/C/001178Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2010-06-10

International Patents for ZYPREXA ZYDIS

See the table below for patents covering ZYPREXA ZYDIS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	127804
Australia	643267
Australia	7518691
Bulgaria	61710
Canada	2041113	DERIVES DE LA THIENOBENZODIAZEPINE ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES (THIENOBENZODIAZEPINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS)
China	1028429
China	1056693

Supplementary Protection Certificates for ZYPREXA ZYDIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	CA 2001 00042	Denmark
0454436	C970015	Netherlands		PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
0454436	9/1997	Austria		PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927

ZYPREXA ZYDIS: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is ZYPREXA ZYDIS and where does it sit in the product line?

ZYPREXA ZYDIS is an orally disintegrating tablet (ODT) formulation of olanzapine. It is marketed by Eli Lilly and Company as a patient-friendly alternative to standard oral olanzapine formats, with dosing aligned to olanzapine’s established schizophrenia and bipolar disorder indications.

Product identity (brand, drug substance, formulation)	Item	Value
Brand	ZYPREXA ZYDIS
Active ingredient	olanzapine
Dosage form	orally disintegrating tablet
Role in franchise	variant within the Zyprexa (olanzapine) portfolio

How has the market treated ZYPREXA ZYDIS versus the broader olanzapine franchise?

The Zyprexa franchise has long faced two structural forces: (1) patent and exclusivity-driven erosion and (2) competitive substitution inside antipsychotic treatment pathways. Within that context, an ODT platform typically preserves share at the margin by improving dosing practicality rather than by creating a clinically differentiated mechanism. The economic footprint therefore tends to track the life cycle of olanzapine rather than a standalone growth curve.

Market dynamics that shape ZYPREXA ZYDIS trajectory

• Generic substitution risk: Olanzapine is off-patent in major markets; branded ODT variants usually face earlier or faster price pressure where generic ODT or low-cost equivalents are available.
• Formulation-based share retention: ODT can support persistence (patient adherence, caregiver use) and may slow conversion to generics relative to non-ODT brands, but it does not immunize against price-driven switching.
• Formulary behavior in schizophrenia/bipolar: Managed care favors lower net cost antipsychotics after therapeutic equivalence and safety profile comparisons settle.
• Long-tail demand: Despite declines, antipsychotics with large existing prescriber familiarity can retain revenue longer than newer categories, especially in stable patients.

Where does ZYPREXA ZYDIS generate revenue risk and upside?

Primary revenue risks

• Net price compression: As payers push for lowest-cost options, branded products with generic availability see margin erosion even if unit demand remains stable.
• Switching triggers: Pharmacy benefit managers and formularies often set step therapy or preferencing that disadvantages branded ODTs.
• Adherence economics do not fully offset price: ODT value is real operationally but typically priced as an add-on, then competed down.

Potential upside levers

• Patient-need segment: Patients who cannot swallow tablets or where caregiver administration matters can sustain a smaller premium segment.
• Prescriber inertia in stabilized patients: If clinicians perceive lower friction with ODT, they may continue it after initiation.

What has the financial trajectory looked like in practice (market decline patterns)?

Publicly reported financial trajectories for branded products generally follow a predictable life cycle in mature, off-patent classes:

1. Pre-generic earnings phase: Higher net sales under brand protection.
2. Post-launch generic erosion: Sales fall as equivalents expand; net price drops faster than volume in many cases.
3. Mature plateau: Unit volume stabilizes at a reduced base; remaining revenue is driven by switches avoidance (form factor, patient tolerance, inertia).
4. Late-stage flattening to decline: Franchise revenues can stabilize briefly, but brand share continues to compress as prescribers and payers convert.

For ZYPREXA ZYDIS specifically, the expected financial profile is consistent with a branded olanzapine formulation operating after generic entry: revenue tends to decline in nominal terms while holding a residual share supported by the ODT attribute.

How does ZYPREXA ZYDIS compare on lifecycle economics to typical branded antipsychotic ODT strategies?

Within antipsychotic ODT strategies, the core commercial premise is retention through ease-of-use. That tends to produce:

• Lower maximum growth than truly differentiated, mechanism-based launches.
• Slower absolute decline than standard oral versions in some managed care environments.
• Higher sensitivity to net-to-gross rebates and formulary placement because the clinical differentiation margin is narrower than in novel drug classes.

What market channels matter most for ZYPREXA ZYDIS demand?

Commercial demand drivers

• Retail pharmacy prescriptions under commercial and government formularies.
• Specialty pharmacy only when required by payer rules, though antipsychotics often remain primarily retail.
• Institutional pharmacy (if administered in care settings) where ODT assists workflow.

Key channel dependency

• The ODT attribute is most valuable at the point of administration and dispensing. That means payer contracting, preferred positioning, and pharmacy chain formulary rules can dominate volume outcomes.

What regulatory and labeling factors affect pricing and access?

ZYPREXA ZYDIS is olanzapine with an ODT dosing form. Access dynamics generally track:

• Label breadth (schizophrenia, bipolar indications) which supports multi-indication demand, but does not prevent substitution when generics exist.
• Safety monitoring requirements that are common to the class and do not create strong exclusive access advantages.

How do current market dynamics shape near-term expectations?

For mature antipsychotic markets, the near-term outlook for an ODT brand like ZYPREXA ZYDIS is typically driven by:

• Persisting conversion pressure from generic olanzapine.
• Formulary management tightening (preferencing and step edits).
• Incremental adherence benefits that help defend a narrow remaining premium segment.

Net result: unless the payer environment provides a durable preferred position, the product tends toward continued volume erosion and further net price compression.

Financial trajectory summary: what the business picture implies

Because ZYPREXA ZYDIS is a formulation variant of an off-patent small molecule, the financial trajectory is best modeled as an ongoing decline with a residual plateau rather than as a growth investment case. The ODT format likely reduces the speed of decline versus a non-ODT branded variant, but it does not change the underlying economic driver: generic availability in the olanzapine molecule.

Key Takeaways

• ZYPREXA ZYDIS is an olanzapine orally disintegrating tablet positioned as a formulation convenience product rather than a mechanism innovation.
• Its market dynamics are dominated by mature antipsychotic class economics: generic substitution, formulary preferencing, and net price compression.
• Financially, the expected trajectory is post-generic erosion moving toward a residual plateau, with ODT helping retention mainly at the margin.
• Near-term performance is likely governed more by payer contracting and net pricing than by clinical differentiation.

FAQs

1) Is ZYPREXA ZYDIS a separate drug from other Zyprexa products?
No. It is an olanzapine formulation variant (ODT) within the Zyprexa franchise.

2) What most strongly influences ZYPREXA ZYDIS sales over time?
Generic availability of olanzapine and payer formulary dynamics that drive net price and switching.

3) Does the ODT format create durable protection against generic erosion?
It can slow substitution for specific patient and caregiver use cases, but it does not remove generic price pressure.

4) Where does ZYPREXA ZYDIS typically sell (channel)?
Primarily through retail pharmacy under payer formularies, with additional usage in care settings where administration convenience matters.

5) Is ZYPREXA ZYDIS a growth opportunity in the current market structure?
As a branded formulation of an off-patent small molecule, it fits a mature lifecycle pattern with continued revenue compression risk.

---

References

[1] Eli Lilly and Company. Zyprexa Zydis (olanzapine) prescribing information.
[2] U.S. Food and Drug Administration. Drug Approval Reports and labeling for Zyprexa Zydis (olanzapine).
[3] FDA Orange Book. Olanzapine products and exclusivity/patent listings for Zyprexa Zydis.
[4] IQVIA/industry summaries on antipsychotic market access and generic substitution trends (general market dynamics).